A Study of Trastuzumab Subcutaneous in Participants With Human Epidermal Growth Factor Receptor-2 (HER2) Positive Early Breast Cancer
This observational study will evaluate the efficacy, safety, tolerability and participant reported quality of life of trastuzumab (Herceptin) subcutaneous (SC) therapy in participants with HER2-positive early breast cancer in routine clinical practice. Data from eligible participants will be collected for the duration of their treatment (approximately 1 year) and for 1-2 years of follow-up.
Breast Neoplasms
DRUG: Trastuzumab
Percentage of Participants With Pathologic Complete Response (pCR) (For Participants Treated in Neo-Adjuvant Setting), According to Response Evaluation Criteria in Solid Tumor (RECIST), or Modified RECIST, or Cheson Criteria (As per Center Practice), Baseline up to approximately 3 years (assessed according to routine center practice)|Percentage of Participants Who Were Alive and Disease Free at Year 2 (For Participants Treated in the Adjuvant Setting), According to RECIST, or Modified RECIST, or Cheson Criteria (As per Center Practice), Year 2
Percentage of Participants with Adverse Events, Baseline up to approximately 3 years|European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) Scores, Baseline, every 12 weeks up to Year 1|European Organization for Research and Treatment of Cancer Breast Cancer Module (EORTC QLQ BR23) Questionnaire Score, Baseline, every 12 weeks up to Year 1|Mean Trastuzumab Dose, Baseline up to Year 1|Duration of Trastuzumab Treatment, Baseline up to Year 1|Percentage of Participants By Reason for Trastuzumab Discontinuation or Interruption, Baseline up to Year 1|Percentage of Participants Who Received Concomitant Treatment (Chemotherapy or Any Other Treatment), Baseline up to Year 1
This observational study will evaluate the efficacy, safety, tolerability and participant reported quality of life of trastuzumab (Herceptin) subcutaneous (SC) therapy in participants with HER2-positive early breast cancer in routine clinical practice. Data from eligible participants will be collected for the duration of their treatment (approximately 1 year) and for 1-2 years of follow-up.